Clinical Trial: A Prospective Clinical Trial of Preliminary Efficacy and Safety of the Combination of 177Lu-FAP-2286 and 177Lu-DOTATATE (Cocktail Therapy) for Advanced Grade 3 Gastroenteropancreatic Neuroendocrine Tumors (FAP-TATE Trial) (China)

China, Sept. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Prospective Clinical Trial of Preliminary Efficacy and Safety of the Combination of 177Lu-FAP-2286 and 177Lu-DOTATATE (Cocktail Therapy) for Advanced Grade 3 Gastroenteropancreatic Neuroendocrine Tumors (FAP-TATE Trial)'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600132243

Registration Time: 2026/09/11

Type: Interventional study

Primary Sponsor: The affiliated hospital of southwest medical university

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=342868

Published by HT Digital Content Services with permission from Health Daily Digest....